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Background. Although sputum smears are the gold standard for diagnosis of tuberculosis, sensitivity in HIV/TB coinfection cases
is low, indicating a need for alternative methods. Urine is being increasingly evaluated. Materials and Methods. A novel method
for detecting Mycobacterium tuberculosis (MTB) in synthetic urine using a combined IMS/ATP assay was evaluated. Preliminary
work established standard ATP conditions and the sensitivity and speciﬁcity of the MTB antibody. Eighty-four blinded samples
in four replicate assays were evaluated for the presence of MTB using labeled immunomagnetic beads for capture. Beads were
separated, washed, and resuspended in broth and added to a microtiter plate. Bioluminescent output was measured and signal-
to-noise ratios were calculated. All samples were plated on Middlebrook 7H10 agar or trypticase soy agar to determine limit of
detection and recoveries. Results and Conclusions. MTB was distinguished from common bacteriuria isolates and other nontarget
bacteria by its ATP results. IMS/ATP successfully detected 19 of 28 samples of MTB in synthetic urine with a limit of detection of
104 CFU/ml. Sensitivity and speciﬁcity were 67.9% and 82.1%, respectively. This assay oﬀers a possible rapid screening method for
HIV-positive patients with suspected coinfection to improve MTB diagnosis.
1.Introduction
There are over 8 million new cases of tuberculosis (TB) an-
nually, with increasing incidence in areas where HIV is pre-
valent [1]. In 2009, there were 9.4 million new TB cases, with
1.1 million among HIV-positive individuals [2]. Sputum
smear microscopy remains the standard for diagnosis. How-
ever, sensitivity varies even among HIV-negative patients,
with an average sensitivity of less than 60%, and is as low as
20%forpatientswithHIV/TBcoinfection[3].Thisisfurther
complicated by an inability to produce sputum among HIV-
positiveindividuals[4–6].Inadditiontosmear-negativepul-
monary TB, HIV-positive individuals tend to have abnormal
chest X-rays and clinical presentations, so diagnosis and
treatment are often delayed [3, 6, 7]. Furthermore, the spu-
tum procedure is limited in diagnosing extrapulmonary in-
fection,whichismorecommonamongpatientsinthisgroup
[3,8,9].Theimpactofsmear-negativediseaseondiagnostics
is signiﬁcant; evennucleic acid ampliﬁcationtests suchas the
Gen-ProbeMTDandRocheAmplicorMTB,whichhavesen-
sitivities greater than 95% in smear-positive cases, have re-
ducedsensitivitiesof40–77%insmear-negativecases[3,10].
Extrapulmonary TB and disseminated disease are more
likely with advanced immunosuppression [8, 10]. The kid-
neys may become involved due to the spread of bacilli
throughthevascularsystemfromfociinthelung[1,4].MTB
bacilli can be excreted through the kidneys and detected in
theurineofpatientswhohavenosymptomsofgenitourinary
involvement [9, 11]. However, although it has been known
since the 1960s that MTB can be found in the urine of pa-
tients with pulmonary TB, urine has been a less reliable clin-
ical sample compared to sputum. Urine has not been recom-
mended for routine diagnosis because the sensitivity of urine
smear microscopy and the yield of urine cultures have been
low; conventional diagnostic methods using urine samples
have had “limited clinical usefulness” [4].2 Tuberculosis Research and Treatment
However, urine has been increasingly evaluated as a
diagnostic sample due to recent developments enabling
the detection of mycobacterial DNA and metabolic products
in urine, particularly among HIV-infected patients [5, 9, 12–
14]. While the number of bacilli in urine varies and ex-
cretion is intermittent, the bacillary load for HIV/TB pa-
tients with disseminated disease may be high [9, 15]. Myco-
bacteriuria may be more prevalent than historically believed
based on urine culture alone, as recent studies have demon-
strated PCR-positive urines with sensitivities up to 66.7% in
smear-negative TB [6, 9]. Additionally, urine samples have
advantagesrelativetootherbiologicalsamplesbecausebacilli
can be easily concentrated [15–17], samples are easy to col-
lect, and there are fewer risks associated with handling [4, 6,
9].
More pressing than the need for alternative diagnostic
sample types is the need for rapid, easy-to-perform tests that
canbeusedinapoint-of-careformat[3,4].Thereareseveral
disadvantages to sputum smear microscopy: (1) it is not
useful where there is a low bacillary load, (2) it is not useful
in cases of extrapulmonary TB, and (3) microscopy can de-
tect other acid-fast bacteria [18]. As already noted, smear-
negative TB and extrapulmonary TB are more common in
HIV-positive patients. Peripheral laboratories rely on micro-
scopy methods, while no diagnostic tests are currently avail-
ableathealthposts[19].AsnotedbytheWorldHealthOrga-
nization, diagnostic limitations have been a “crucial barrier”
to meeting the challenges of HIV-associated TB [20].
Immunomagnetic separation (IMS) has been successful-
ly used to concentrate and recover pathogenic mycobacteria,
including MTB [21, 22]. IMS also enables speciﬁc target cap-
tureanddecreasesparticulateinterferenceindetectionassays
[23, 24]. ATP bioluminescence assays have demonstrated
utility in bacteriuria screening [25, 26], quality control of
BCG vaccines [27], and MTB antibiotic susceptibility testing
[28]. Combining immunocapture with an ATP-based cell
viability assay can provide rapid, speciﬁc, semiquantitative
detection of live cells [29–31]. The method presented here
combines IMS with an ATP-based cell viability assay to pro-
vide rapid, speciﬁc detection of MTB in urine. The method
is easy to perform and could have use in settings where the
rate of HIV/TB co-infection is high.
The objectives of this work were to study (1) the sen-
sitivity and speciﬁcity of the MTB antibody, (2) the ATP
amountreleasedfromMTBrelativetootherorganismsusing
a standard ATP assay, (3) the eﬀect of incubation time and
urine pH on IMS/ATP results, and (4) the possible detection
of MTB in synthetic urine.
2.MaterialsandMethods
2.1. Antibodies. Aﬃnity-puriﬁed rabbit polyclonal antibody
to MTB (BIODESIGN International, Saco, ME) in phos-
phate-buﬀered saline (PBS) and aﬃnity-puriﬁed goat anti-
rabbit antibody conjugated to horseradish peroxidase in PBS
(Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD)
were used as detection antibodies in ELISA. Biotin-labeled
rabbit polyclonal antibody to MTB in PBS (BIODESIGN In–
ternational, Saco, ME) was used as the capture antibody in
the IMS/ATP assay. The antibody was immobilized on
M280 Streptavidin Dynabeads (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Antibody-labeled
beads were stored for up to one week at 4◦C until use.
2.2. Bacteria. MTB or Mycobacterium tuberculosis ATCC
25177 was the target microorganism for all assays. Nontarget
microorganisms included common urine isolates [26], other
mycobacteria, and Candida because of their morphological
similarities to MTB. These strains were either ATCC strains
or obtained from the University of South Florida Advanced
Biosensors Laboratory (ABL) collection and included Myco-
bacterium smegmatis ABL 539, Mycobacterium avium ATCC
25921, Mycobacterium intracellulare ATCC 13950, Mycobac-
terium gordonae ATCC 14470, Rhodococcus rhodochrous ABL
538, Candida albicans ABL 537, Staphylococcus aureus ATCC
25923, Staphylococcus epidermidis ATCC 12228, Staphylococ-
cus simulans ATCC 11631, Enterococcus faecalis ATCC 19433,
Escherichiacoli K12 ABL 552, Pseudomonas aeruginosa ATCC
15442, and Klebsiella pneumoniae ATCC 29019. Working
stocksofnonmycobacterialstrainspreparedfromfrozencul-
tures were grown for 18h at 37◦C in tryptic soy broth (TSB;
BD, Franklin Lakes, NJ). Working stocks of mycobacteria
prepared from frozen cultures were grown for two days to
three weeks (depending on the strain) at 37◦C and 5% CO2
on Middlebrook 7H10 agar (BD, Franklin Lakes, NJ). All
working stocks were maintained at 4◦Cf o ru pt o3 0d a y s .A
fresh culture of MTB was incubated on a weekly basis for use
in assays. Other bacterial strains used were grown overnight
on tryptic soy agar (BD, Franklin Lakes, NJ) at 37◦C.
2.3. Sample. Synthetic urine was purchased from Ricca
Chemical Company (Arlington, TX). Synthetic urine has
beenusedinavarietyofstudies,includingmethodvalidation
studies [32–34]. The urine contains urea, sodium chloride,
magnesiumsulfateheptahydrate,calciumchloridedihydrate,
and water. Urine pH was adjusted from ∼8 . 4t o7 .1 ± 0.1o r
5.5 ± 0.1 to determine whether urine pH inﬂuenced IMS.
Based on these results, urine pH was adjusted to 7.1 ± 0.1
for all blinded assays (described in what follows).
2.4. ELISA. Cells were suspended in 0.01M PBS with 0.1%
Tween-80(PBST80).Glassbeads(0.1mm,BioSpecProducts,
Inc., Bartlesville, OK) were added to mycobacterial suspen-
sions to aid in dispersion. Cell suspensions were serially dil-
uted (1:10) in PBST80, and consecutive serial dilutions were
addedtoMaxiSorp96-wellmicrotiterplates(NalgeNuncIn-
ternational, Rochester, NY) in triplicate (100µL/well) and
incubated for 1h at 37◦C. Plates were washed 3 times with
PBS containing 0.05% Tween-20 (PBST), then coated with
100µL primary antibody in blocking buﬀer and incubated
for 30 minutes at 25◦C. Plates were washed again, 100µL
of HRP-labeled secondary antibody in blocking buﬀer was
added to each well, and plates were incubated for 30min at
25◦C. Plates were washed a ﬁnal time, and peroxidase acti-
vitywasdetectedusingaQuantaBlukit(ThermoFisher,Item
15169) according to manufacturer instructions. Plates were
read on a SpectraMax Gemini XS with the followingTuberculosis Research and Treatment 3
parameters: 340nm excitation, 470nm emission, 455nm
cutoﬀ, and PMT set to auto.
Each organism was assayed in duplicate. Signal-to-noise
ratios (S:N) for each strain at each concentration were de-
termined by dividing the raw ﬂuorescence by the average
background ﬂuorescence. Triplicate S:N from duplicate pla-
tes were averaged and standard deviations were calculated.
Average S:N greater than or equal to 2.0 were considered
positive.
2.5. Standard ATP Assays. Cells were suspended in Mueller
Hinton II broth (MHII) containing 0.1% Tween-80 (MHII-
80) and serially diluted (1:10) in MHII-80. Consecutive
serial dilutions were added in triplicate (100µL/well) to
Lumitrac 600 microtiter plates (BioExpress, Kaysville, UT).
MHII-80 without cells was used to establish background.
BacTiter-Glo reagent was added to each well (100µL/well),
contents were mixed brieﬂy on an orbital shaker, and bio-
luminescent output was measured on a GloMax 96 lumino-
meter (Promega, Madison, WI) at 5, 10, 15, 20, and, in some
assays, 40 minutes. S:N for each strain at each concentration
were determined by dividing the raw ﬂuorescence by the av-
erage background ﬂuorescence.
2.6.IMS/ATPAssays. Initially,standardIMS/ATPassayswere
completed using MTB suspended in PBST80. Twenty micro-
liters of antibody-labeled beads were added to each sample,
which were then incubated with shaking for 60 minutes at
37◦C. Beads were separated from the sample using a magnet,
the sample was removed, and beads were washed three
times with PBST then resuspended in MHII broth. MHII
broth containing only labeled beads was used to establish
background. Samples (100µL per well) were added to
Lumitrac 600 plates followed by 100µL per well of BacTiter-
Glo reagent. Contents of the plates were mixed brieﬂy on an
orbital shaker, incubated for 5min at 25◦C ,a n dr e a da t5 ,
10, 15, and 20 minutes using a GloMax 96 luminometer with
no delay and 1sec integration. Sample S:N were determined
by dividing the raw ﬂuorescence by the average background
ﬂuorescence.
Subsequently, the IMS/ATP assay was evaluated using
MTB suspended in synthetic urine. The procedure was the
same except sample incubation time was 30–60min at 37◦C
to determine the impact of incubation time on IMS/ATP re-
sults. For the ﬁnal set of IMS/ATP assays in synthetic urine,
sample incubation time was 30min, and samples were blind-
ed and number coded. For all blinded samples, four replicate
w e l l sa te a c hc o n c e n t r a t i o nw e r ea v e r a g e df o re a c ht i m e
point.Samplecodeswererevealedafterassaycompletionand
analysis.
2.7. Statistical Analysis. To evaluate the eﬀect of urine pH
and incubation time, paired t-tests were performed compar-
ing S:N at each concentration from 103 to 106 CFU/mL at
each pH or for each incubation time (SigmaPlot 11, Systast
Software, Inc., Chicago, IL). Diﬀerences in means were con-
sidered statistically signiﬁcant for P ≤ 0.05 (95% conﬁdence
level).
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Figure 1: Standard ATP assay results for S. aureus and E. coli K12
at 106 and 107 CFU/mL. Organisms were suspended and serially
diluted in Mueller Hinton II broth containing 0.1% Tween-80 and
evaluated using the BacTiter-Glo basic ATP assay.
3. Results and Discussion
3.1. ELISA. The detection limit of MTB by ELISA was ap-
proximately 105 CFU/mL. Some cross-reactivity with M.
smegmatis, E. coli K12, K. pneumoniae,a n dP. aeruginosa was
noted, but S:N for these strains ranged from 2.5 to 3.4 RLU,
slightly above the positive cutoﬀ of 2 RLU. There was in-
creased cross-reactivity for these strains at concentrations
near 107 CFU/mL; therefore, the assay would be utilized for
screening purposes rather than conﬁrmation due to the pot-
ential for false positives. Also, the relatively high detection
limit of the assay would not positively identify low bacillary
load samples. However, with the standard practice of cen-
trifugation, ﬁltration, and/or pooling of urine samples com-
bined with IMS, the numbers of tubercle bacilli could be in
the detectable range.
3.2. Standard ATP Assays. Generally, Gram-positive and
Gram-negativebacteriaexhibiteddecreasingsignalovertime
asATPwasconsumed(Figure 1).Incontrast,organismswith
a thicker cell wall, including the mycobacteria and Candida,
exhibited increasing signal over time due to the additional
time required to break down the cell walls to release ATP
(Figure 2).Theincreaseinsignalisadistinguishingfeatureof
mycobacteria and Candida that could allow diﬀerentiation
from other common organisms associated with bacteriuria,
namely, E. coli and mixed Gram-positive cocci [26]. It was
also routinely observed that MTB had a modest increase in
signal relative to other mycobacteria. The signal at 20min
was 0.96–1.06 times higher than the signal at 5min for
MTB, whereas the signal at 20min for M. smegmatis, M.
gordonae,an dM.intracellulare was1.65–3.26, 1.19–1.80, and
1.20–1.55 times higher, respectively, than the signal at 5min.
The signal for C. albicans at 20min was 2.8–3.2 times higher4 Tuberculosis Research and Treatment
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Figure 2: Standard ATP assay results for various mycobacteria
and Candida albicans at approximately 106 CFU/ml. Organisms
were suspended and serially diluted in Mueller Hinton II broth
containing 0.1% Tween-80 and evaluated using the BacTiter-Glo
basic ATP assay.
than the signal at 5min. The modest increase in MTB sig-
nal could enable diﬀerentiation between MTB and other my-
cobacteria or C. albicans in a screening assay. It should be
noted, however, that these results may not mirror real-
world samples. C. albicans was grown for 18h and used im-
mediately, whereas the mycobacteria were grown for 2 days
(M. smegmatis) up to 3 weeks (MTB), so the metabolic ac-
tivity of the mycobacteria varied in comparison and could
have been lower due to diﬀerences in growth phase.
Furthermore, only evaluating samples for a change in
S:N over time would lead to misidentiﬁcation of samples
because of noted cross-reactivity in ELISA and similar in-
creases in S:N for other mycobacteria and C. albicans.T h e
standard ATP results for MTB revealed that, generally, at
least one time point after the ﬁrst time point (T1) will be
greater than T1 and that the average S:N over all four time
points should be greater than T1 due to the increases in S:N.
Therefore, data for the blinded assays were evaluated on two
factors: (1) whether the S:N at any time point after T1 was
greater than T1 and (2) whether the average S:N over all
four time points divided by T1 was greater than 1. For this
analysis, because MTB demonstrated increasing S:N over
time, factor (2) was only evaluated if there was an increase in
S:N after T1; otherwise, the sample was considered negative.
3.3. IMS/ATP Assays
3.3.1. Initial Assays. IMS/ATP parameters were established
through preliminary assays. Standard IMS assays in PBST80
revealed a clear aﬃnity of the MTB antibody for MTB over
nontargets using IMS (Figure 3), which is signiﬁcant given
the cross-reactivity observed in ELISA. Additionally, side-by-
side IMS/ATP assays performed using urine at pH 5.5 ± 0.1
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Figure 3: IMS/ATP assay at approximately 106 CFU/ml in PBS
containing 0.1% Tween-80.
and 7.1±0.1 revealed that there was no signiﬁcant diﬀerence
among S:N and that S:N were in the same log for the same
concentration regardless of pH. Recoveries as determined
by total viable counts were also similar (data not shown).
Based on these data coupled with normal human urine nor-
mally being close to pH 7 [35], all subsequent assays were
performed at pH 7.1 ±0.1.
There was no signiﬁcant diﬀerence in mean S:N for ei-
ther 30 or 60min incubation time, with mean S:N for MTB
being slightly higher with 30min incubation, while mean
S:NforE. coli K12 were slightly higher with a 60min in-
cubation. Increased incubation time may increase the poten-
tial for nontarget binding while failing to improve detection
of the target. Therefore, a 30min incubation period was im-
plemented for all subsequent assays. There were several ad-
vantages to this approach: (1) antibody-antigen binding is
rapid and strong, and a 60min incubation period may be
unnecessary, (2) a short incubation period would not in-
crease the metabolic activity or enhance ATP levels for slow-
growing MTB as would be expected with an organism that
has a shorter generation time, and (3) overall assay time was
reduced.
3.3.2. Blinded Assays. One blinded assay including 20 sam-
ples (4 MTB and 16 nontargets) was performed to evaluate
the sample analysis described in Section 3.2.A l lf o u rM T B
samples were identiﬁed using this analysis. In addition, a
cutoﬀ for factor (2) was identiﬁed based on the results for
the nontargets. The mean for average S:N/T1 was 0.95±0.2,
making the upper limit for negative samples 0.97. Therefore,
if samples met factor (1), they were considered positive for
averageS:N/T1 ≥0.98.Fourreplicateassayswerecompleted
using this analysis. The results for MTB are reported in
Table 1.Tuberculosis Research and Treatment 5
Table 1: Summary results for detection of MTB in synthetic urine—blinded assays.
Replicate Conc. (CFU/mL) S:N at T1 S:N at any time point > T1 Average S:N (T1–T4) Average
S:N/T1 Send for conﬁrmation
1
105 17.60 X 20.40 1.16 Yes
105 12.69 X 18.45 1.45 Yes
105 15.81 X 18.11 1.15 Yes
104 2.14 2.07 0.97 No
104 1.64 X 1.72 1.05 Yes
104 2.30 X 4.09 1.78 Yes
103 1.02 0.98 0.96 No
2
106 9.86 X 9.75 0.99 Yes
106 12.99 X 12.83 0.99 Yes
106 11.27 X 11.44 1.01 Yes
105 4.00 3.76 0.94 No
105 2.71 2.65 0.98 No
105 3.61 X 3.58 0.99 Yes
104 12.47 X 12.24 0.98 Yes
104 15.43 15.05 0.98 No
3
106 4.45 X 4.60 1.03 Yes
106 3.83 3.74 0.98 No
106 3.72 X 3.75 1.01 Yes
105 1.64 X 1.64 1.01 Yes
105 1.16 1.11 0.95 No
105 1.23 1.19 0.97 No
104 1.11 X 1.09 0.98 Yes
104 1.12 1.09 0.97 No
4
106 1.71 X 1.93 1.13 Yes
106 8.57 X 14.65 1.71 Yes
106 1.39 X 1.40 1.01 Yes
106 5.62 X 7.20 1.28 Yes
105 1.65 X 1.67 1.01 Yes
Table 2: Summary results for false positives in the blinded assays.
Organism Replicate Conc.
(CFU/mL)
S:Nat
T1
S:Natanytime
point > T1
Average S : N
(T1–T4)
Average
S:N/T1 Send for conﬁrmation
M. smegmatis
11 0 6 23.80 X 57.50 2.42 Yes
21 0 6 4.29 X 4.52 1.05 Yes
21 0 6 3.98 X 4.26 1.07 Yes
M. intracellulare 31 0 6 1.56 X 1.56 1.00 Yes
C. albicans
31 0 6 347.1 X 378.0 1.09 Yes
31 0 6 264.2 X 392.4 1.49 Yes
31 0 5 44.76 X 48.48 1.08 Yes
41 0 5 15.81 X 28.14 1.78 Yes
41 0 5 19.03 X 32.6 1.71 Yes
41 0 4 1.75 X 2.92 1.67 Yes
K. pneumoniae 31 0 6 1.09 X 1.05 0.96 No
E. faecalis 31 0 6 7.95 X 7.73 0.97 No
41 0 6 13.54 X 12.87 0.95 No6 Tuberculosis Research and Treatment
Table 3: Mean S:N for detection of M. tuberculosis by IMS/ATP.
Data is averaged from the four replicates reported.
Mean concentration
(CFU/mL) 2.82E +06 2.82E +0 5 2 .82E +04
Mean S:N
5min 8.74 2.16 1.16
10min 10.01 2.25 1.15
15min 11.26 2.39 1.13
20min 12.46 2.43 1.11
Overall, 19 of 28 MTB samples were ﬂagged for con-
ﬁrmation, resulting in a sensitivity of 67.9%. This is much
higher than the approximately 20% sensitivity typical of
sputum smear microscopy in HIV-positive patients with
suspected TB [26] and is on a par with alternative diagnostic
tests like the LAM ELISA, which has a reported sensitivity of
67–85% in HIV-positive patients [5]. All 19 ﬂagged samples
exhibited an increase in S:N for at least one time point
after T1, and all yielded an average S:N/T1 of 0.98 or
greater. None of the samples considered negative exhibited
an increase in S:N for any time point after T1, and this
resultwasnotrestrictedbyconcentration.Oneofonesample
at 103 CFU/mL, three of seven at 104, four of ten at 105,
and one of ten at 106 were negative by this analysis. The
variability in results could have been impacted by several
factors, including the age of the cultures, whose metabolic
activity may have been signiﬁcantly lower than what would
be observed for bacteria isolated from an active infection, as
well as the use of spiked, synthetic urine. It would be im-
portant to evaluate this method using actual clinical samples
to determine whether these factors have, in fact, inﬂuenced
the results.
The speciﬁcity of the assay was 82.1%, with 10 false-
positives out of 56 total samples (Table 2). All of the false-
positives met both factors of the analysis—they exhibited an
increase in S:N at any time point after T1, and they yield-
ed an (average S:N/T1) > 1.0 in all instances. Two organ-
isms—K. pneumoniae and E. faecalis—satisﬁed factor (1) in
three instances, but none satisﬁed factor (2), and thus were
considered negative. As for M. smegmatis, the false posi-
tive was not surprising given the cross-reactivity noted at
106 CFU/mL in ELISA. However, M. smegmatis is rarely
found in urine and not at the concentrations evaluated [36,
37]. Therefore, M. smegmatis was not evaluated in replicates
3a n d4 .
Two observations can be made for C. albicans. First,
standard ATP assays revealed that C. albicans generally
yields higher overall signals and greater increases relative
to MTB. This is evident from the S:N at T1 (Table 2), as
well as the results for average S:N/T1 relative to MTB. The
mean average S:N/T1 for C. albicans w a s1 . 4 7v e r s u s1 . 1 4
for positive MTB samples. Second, C. albicans is not as com-
monly isolated from urine specimens as other organisms, so
it is less likely to pose a problem with real-world samples.
Yeasts comprised only 4 of 178 samples (0.02%) in one study
of microorganisms isolated from 400 urine specimens [26].
Finally, the only other organism to result in a false-posi-
tive was M. intracellulare. This result is signiﬁcant since
M.intracellulareispartoftheM.aviumcomplexknowntobe
anopportunisticpathogenofimmunocompromisedpatients
[38]. While only one of seven M. intracellulare samples and
none of ﬁve M. avium samples resulted in a false-positive, it
would be important to evaluate these organisms further in
future assays.
ThemeanS:Nacrossreplicatesforagivenconcentration
were consistent, with S:N at 104 and 105 CFU/mL in the
same log (Table 3). An increase in S:N over time was ob-
served for the two highest concentrations but not for the
samples at 104 CFU/mL, which may explain the inconsistent
detection of this concentration in individual assays.
The described IMS/ATP assay could have utility as a
screening assay in reference or peripheral laboratories where
HIV/TB co-infection rates are high. The assay is rapid, takes
less than 1h to complete, and requires minimal reagents and
equipment. Even with potential cross-reactivity, the assay
has merit, because the objective is to screen, rather than
conﬁrm. This novel assay is potentially useful as a diagnostic,
screening assay for the detection of MTB in HIV-positive
patients.
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